S1E2: The Power of N-of-1

What happens when the patient sitting across from you is the only person in the world with their specific condition? In traditional medicine, that's a problem. For Harry Wilton-Clark, it's the whole point. In this episode of Science at the Fifty-Third Degree, host Dr. Nayiar Shahid talks with Harry Wilton-Clark, a researcher at the University of Alberta's Women and Children's Health Research Institute, about a quiet revolution happening at the edges of medicine — the rise of N-of-1 therapies. These are treatments designed not for thousands of patients, but for one. Harry's work focuses on Duchenne muscular dystrophy, a rare and fatal disease that strikes children. Using a technique called exon skipping therapy, his lab designs what he calls "genetic band-aids" — molecules that bind to a specific mutation in a patient's DNA and hide it from the body, allowing it to function more normally. The therapy isn't built for a population. It's built for a child. This episode covers: What Duchenne muscular dystrophy is and why it's so difficult to treat How exon skipping therapy works — and what a "genetic band-aid" actually does Why traditional clinical trials fail rare disease patients — and what N-of-1 trials offer instead How patient families and advocacy organizations are driving research breakthroughs What it felt like when a mouse that wouldn't run — finally ran Why a single patient's treatment could become a master key for thousands of othersHarry recently represented Canada at the Falling Walls Lab in Berlin — one of 100 researchers selected from around the world to present work breaking the boundaries of science's biggest problems. The wall he chose to break: the one standing between a child and a cure.